Biotech

Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

MONTREAL, QUEBEC: Ibalizumab Maintains Significant Viral Load Reduction and Increases CD4+ T cells in Patients with Multidrug Resistant HIV-1 over 24 Weeks Results Presented in Late-Breaker Session at CROI 2017 Support ...

Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock

LEXINGTON, MA: ...

Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock

LEXINGTON, MA: ...

Treos Bio Raises $8 Million in Private Investment Round

SAN FRANCISCO, CA and LONDON, UNITED KINGDOM: Funding will carry company through early-stage clinical trial of its precision vaccine for colorectal cancer ...

Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government

SYDNEY, AUSTRALIA: ...

Taconic Biosciences Launches New EZcohort(TM) Program Improving Access to Mouse Models

HUDSON, NY: ...

Marina Biotech Announces a License Agreement to SMARTICLES

CITY OF INDUSTRY, CA: ...

Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial

LEXINGTON, MA: ...

Trillium Therapeutics to Present at Investor and Scientific Conferences in February

TORONTO, ONTARIO: ...

Immunovaccine''s Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in Ovarian Cancer in Combination With Approved Anti-PD-1 Drug

HALIFAX, NOVA SCOTIA: University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined With D ...